RT Journal Article
SR Electronic
T1 Hybrid and vaccine-induced immunity against SARS-CoV-2 in MS patients on different disease-modifying therapies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.28.22276989
DO 10.1101/2022.06.28.22276989
A1 Ilya Kister
A1 Ryan Curtin
A1 Jinglan Pei
A1 Katherine Perdomo
A1 Tamar E. Bacon
A1 Iryna Voloshyna
A1 Joseph Kim
A1 Ethan Tardio
A1 Yogambigai Velmurugu
A1 Samantha Nyovanie
A1 Andrea Valeria Calderon
A1 Fatoumatta Dibba
A1 Stanzin Idga
A1 Marie I. Samanovic
A1 Pranil Raut
A1 Catarina Raposo
A1 Jessica Priest
A1 Mark Cabatingan
A1 Ryan C. Winger
A1 Mark J. Mulligan
A1 Yury Patskovsky
A1 Gregg J. Silverman
A1 Michelle Krogsgaard
YR 2022
UL http://medrxiv.org/content/early/2022/06/28/2022.06.28.22276989.abstract
AB Objective To compare ‘hybrid immunity’ (prior COVID-19 infection plus vaccination) and post-vaccination immunity to SARS CoV-2 in MS patients on different disease-modifying therapies (DMTs) and to assess the impact of vaccine product and race/ethnicity on post-vaccination immune responses.Methods Consecutive MS patients from NYU MS Care Center (New York, NY), aged 18-60, who completed COVID-19 vaccination series ≥6 weeks previously were evaluated for SARS CoV-2-specific antibody responses with electro-chemiluminescence and multiepitope bead-based immunoassays and, in a subset, live virus immunofluorescence-based microneutralization assay. SARS CoV-2-specific cellular responses were assessed with cellular stimulation TruCulture IFNγ and IL-2 assay and, in a subset, with IFNγ and IL-2 ELISpot assays. Multivariate analyses examined associations between immunologic responses and prior COVID-19 infection while controlling for age, sex, DMT at vaccination, time-to-vaccine, and vaccine product.Results Between 6/01/2021-11/11/2021, 370 MS patients were recruited (mean age 40.6 years; 76% female; 53% non-White; 22% with prior infection; common DMT classes: ocrelizumab 40%; natalizumab 15%, sphingosine-1-phosphate receptor modulators 13%; and no DMT 8%). Vaccine-to-collection time was 18.7 (±7.7) weeks and 95% of patients received mRNA vaccines. In multivariate analyses, patients with laboratory-confirmed prior COVID-19 infection had significantly increased antibody and cellular post-vaccination responses compared to those without prior infection. Vaccine product and DMT class were independent predictors of antibody and cellular responses, while race/ethnicity was not.Interpretation Prior COVID-19 infection is associated with enhanced antibody and cellular post-vaccine responses independent of DMT class and vaccine type. There were no differences in immune responses across race/ethnic groups.Competing Interest StatementIK served on the scientific advisory board for Biogen Idec, Genentech, Alexion, EMDSerono, Horizon; received consulting fees from Roche; and received research support from Guthy-Jackson Charitable Foundation, National Multiple Sclerosis Society, Biogen Idec, Serono, Genzyme, and Genentech/Roche; he receives royalties from Wolters Kluwer for 'Top 100 Diagnosis in Neurology'. GJS received honoraria from BMS, Eli Lilly and Genentech, and research support from BMS, Genentech, Lupus Research Alliance, NIH-NIAMS, NIH-NIAID and NIH-NILB. MK is on the scientific advisory board for NexImmune and Genentech and received research support from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Genentech, Novartis, the Mark Foundation, NIH-NIGMS and NIH-NCI. CR is employee and shareholder of F. Hoffmann-La Roche. MJM reported the following potential competing interests: laboratory research and shareholder of F. Hoffmann-La Roche Ltd; clinical trials contracts for vaccines or MAB vs. SARS-CoV-2 with Lilly, Pfizer-BioNTech, and Sanofi; personal fees for Scientific Advisory Board service from Merck, Meissa Vaccines, and Pfizer-BioNTech; contract funding from USG/HHS/BARDA for research specimen characterization and repository; research grant funding from USG/HHS/NIH for SARS-CoV-2 vaccine and MAB clinical trials. JP, PR, JP, MC, and RCW are employees of Genentech, Inc. and shareholders of F. Hoffmann-La Roche. RC, KP, TEB, JK, ET, IV, YV, SN, AVC, FD, SI, MS, YP have nothing to disclose.Funding StatementThis work was supported by an unrestricted investigator-initiated grant from Genentech.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the NYU Grossman School of Medicine gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.